Austco Healthcare (AHC) Q2 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 TU earnings summary
19 Aug, 2026Executive summary
Forecasts strong revenue and EBITDA growth for the first half of FY25 compared to the same period last year.
Growth driven by both organic performance and recent acquisitions, Teknocorp and Amentco.
Integration of acquisitions has expanded capabilities and market presence.
Financial highlights
Revenue for 1HFY25 forecast at $35.8m–$36.9m, up ~59% year-over-year from $22.8m.
EBITDA forecast at $4.5m–$5.1m, up ~129% year-over-year from $2.1m.
Organic revenue growth estimated at ~19%; organic EBITDA growth at ~85%.
Outlook and guidance
Second half revenues and EBITDA are historically higher than first half results.
Final audited results for the period will be released in late February 2025.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Austco Healthcare
- Record revenue, profit, and recurring software growth, with strong cash and major contract wins.AHC
H2 2026 - Record revenue and profit growth driven by contracts, acquisitions, and software innovation.AHCInvestor presentation
- Record revenue, profit, and software growth driven by acquisitions and innovation.AHCInvestor presentation
- Record revenue and EBITDA growth, global expansion, and strong cash position drive future outlook.AHCInvestor presentation
- Record revenue and profit growth, with strong order backlog and positive growth outlook.AHCH2 2024
- Record Q1 revenue growth and major contract wins drive strong outlook for continued expansion.AHCQ1 2025 TU
- Record revenue and EBITDA growth, strong profit, and robust order book support future performance.AHCH1 2025
- Revenue and EBITDA surged year-over-year, with strong cash flow and robust contracted revenue.AHCQ4 2025 TU
- Record revenue and EBITDA growth, strong cash, and robust orders position for continued expansion.AHCH2 2025